Kymera Therapeutics, Inc.
NASDAQ:KYMR
40.11 (USD) • At close December 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 109.966 | 68.395 | 47.976 | 31.004 | 76.015 | 41.26 |
| Short Term Investments
| 264.915 | 338.771 | 394.442 | 265.198 | 15.942 | 0 |
| Cash and Short Term Investments
| 374.881 | 559.494 | 567.605 | 458.733 | 91.957 | 41.26 |
| Net Receivables
| 18.762 | 2.537 | 0.135 | 1.433 | 0 | 0.148 |
| Inventory
| 0 | -12.25 | -8.99 | -163.387 | 0 | 0 |
| Other Current Assets
| 11.674 | 9.713 | 8.72 | 4.704 | 0.888 | 0.382 |
| Total Current Assets
| 405.317 | 559.494 | 567.605 | 302.339 | 92.845 | 41.79 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 101.079 | 13.334 | 11.881 | 10.841 | 22.083 | 2.242 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 61.434 | 152.328 | 125.187 | 162.531 | 1.774 | 0.199 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 7.929 | -122.022 | -98.768 | 11.464 | 0 | 0 |
| Total Non-Current Assets
| 170.442 | 43.64 | 38.3 | 184.836 | 23.857 | 2.441 |
| Total Assets
| 575.759 | 603.134 | 605.905 | 487.175 | 116.702 | 44.231 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 7.075 | 4.335 | 4.005 | 4.368 | 3.276 | 2.056 |
| Short Term Debt
| 12.69 | 7.886 | 7.198 | 6.522 | 3.377 | 0.302 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 37.883 | 63.26 | 101.034 | 170.39 | 23.349 | 2.319 |
| Other Current Liabilities
| 28.043 | 23.862 | 19.6 | 7.175 | 4.568 | 2.329 |
| Total Current Liabilities
| 85.691 | 63.26 | 101.034 | 110.617 | 34.57 | 4.687 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 156.658 | 26.784 | 28.728 | 29.464 | 17.816 | 0.393 |
| Deferred Revenue Non-Current
| 16.768 | 28 | 39.295 | 77.838 | 29.642 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | -53.659 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| -78.329 | -13.144 | -14.298 | -14.632 | 109.08 | 73.587 |
| Total Non-Current Liabilities
| 95.097 | 49.723 | 45.233 | 92.67 | 156.538 | 73.98 |
| Total Liabilities
| 180.788 | 112.983 | 146.267 | 203.287 | 191.108 | 78.667 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 487.175 | 109.08 | 73.429 |
| Common Stock
| 0.006 | 0.006 | 0.005 | 0.004 | 0 | 0 |
| Retained Earnings
| -530.752 | -383.79 | -228.982 | -128.765 | -76.456 | -35.21 |
| Accumulated Other Comprehensive Income/Loss
| -0.552 | -4.949 | -0.66 | -0.128 | 0.006 | 0 |
| Other Total Stockholders Equity
| 926.269 | 878.884 | 689.275 | 412.777 | -107.036 | -72.655 |
| Total Shareholders Equity
| 394.971 | 490.151 | 459.638 | 283.888 | -74.406 | -34.436 |
| Total Equity
| 394.971 | 490.151 | 459.638 | 283.888 | -74.406 | -34.436 |
| Total Liabilities & Shareholders Equity
| 575.759 | 603.134 | 605.905 | 487.175 | 116.702 | 44.231 |